EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review

Zhibin Xu, Nan Hu, Qitao Chen, Yue Zhou, Yunye Huang, Songhao Hu, Haoru Jin, Yubo Tang

Frontiers in Endocrinology · 27.05.2025 · 16

DOI: 10.3389/fendo.2025.1480195 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Endocrinology, online erschienen am 27.05.2025. Verfasst von Zhibin Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, First Affiliated Hospital of Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Graves Ophthalmopathy, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Teprotumumab has shown significant efficacy in treating Thyroid Eye Disease (TED), but its adverse effects require careful management. Key reactions include hearing impairment, hyperglycemia, and potential exacerbation of pre-existing inflammatory bowel disease (IBD). Hearing impairment, likely due to inhibition of the insulin-like growth factor 1 receptor (IGF-1R), manifests as more severe sensorineural changes. Hyperglycemia results from disrupted growth hormone feedback and may be worsened by prior glucocorticoid use. Although teprotumumab does not appear to induce new diabetes cases, it can exacerbate existing hyperglycemia. Cognitive issues, infusion reactions, and other adverse effects, such as muscle cramps and weight loss, have also been observed. Management requires careful patient screening, particularly for those with histories of hearing loss, diabetes, or IBD. Further research is essential to elucidate the underlying mechanisms of these adverse effects and develop targeted preventive strategies to improve the safety and efficacy of teprotumumab in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGraves OphthalmopathyDrug-Related Side Effects and Adverse ReactionsHumansHearing LossBlood GlucoseDisease ProgressionInflammatory Bowel DiseasesReceptor, IGF Type 1Diabetes MellitusOtotoxicity

Stichwörter der Autor:innen

adverse reactionshearing impairmenthyperglycemiainflammatory bowel disease (IBD)teprotumumabthyroid eye disease (TED)

Substanzen

teprotumumabAntibodies, Monoclonal, HumanizedBlood GlucoseReceptor, IGF Type 1

Autor:innen und Institutionen

  • Department of Clinical Research, First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Clinical Research Center (CRC), The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Department of Pharmacy, Sanming Integrative Medicine Hospital, Sanming, Fujian, China.
  • Department of Otolaryngology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Department of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Department of Thoracic Surgery, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou M…

Zitieren

APA

Xu, Z., Hu, N., Chen, Q., Zhou, Y., Huang, Y., Hu, S., Jin, H., & Tang, Y. (2025). Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review. Frontiers in Endocrinology, 16. https://doi.org/10.3389/fendo.2025.1480195

Vancouver

Xu Z, Hu N, Chen Q, Zhou Y, Huang Y, Hu S, et al. Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review. Frontiers in Endocrinology. 2025;16. doi:10.3389/fendo.2025.1480195

BibTeX
@article{Xu2025,
  author = {Xu, Zhibin and Hu, Nan and Chen, Qitao and Zhou, Yue and Huang, Yunye and Hu, Songhao and Jin, Haoru and Tang, Yubo},
  title = {Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review},
  journal = {Frontiers in Endocrinology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fendo.2025.1480195}
}
Kostenlos starten →